使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day, and thank you for standing by. Welcome to the Q3 2026 Universal Health Services earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
大家好,感謝您耐心等候。歡迎參加環球健康服務(Universal Health Services)2026 年第三季(Q3)財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to hand the conference over to your first speaker today, Darren Lehrich, Vice President of Investor Relations. Please go ahead.
現在我想把會議交給今天的第一位講者——投資人關係副總裁 Darren Lehrich。請開始。
Darren Lehrich - Vice President of Investor Relations
Darren Lehrich - Vice President of Investor Relations
Good morning, and welcome to Universal Health Services third-quarter 2026 earnings conference call. I'm Darren Lehrich, Vice President of Investor Relations. With me this morning are our President and CEO, Marc Miller; and our Chief Financial Officer, Steve Filton. Marc and Steve will offer some remarks about the quarter, and then we'll open up to Q&A. During today's conference call, we will be using words such as believes, expects, anticipates, estimates and similar words that represent forecasts, projections and forward-looking statements.
各位早安,歡迎參加環球健康服務 2026 年第三季財報電話會議。我是投資人關係副總裁 Darren Lehrich。今天早上與我一同出席的有我們的總裁兼執行長 Marc Miller,以及財務長 Steve Filton。Marc 與 Steve 將先就本季表現發表一些評論,之後我們將開放問答。在今天的電話會議中,我們將使用例如 believes、expects、anticipates、estimates 等詞語,以及其他類似用語,這些用語代表預測、推估與前瞻性陳述。
For anyone not familiar with the risks and uncertainties inherent in these forward-looking statements. We recommend the careful reading of the section on Risk Factors and Forward-Looking Statements and Risk Factors in our Form 10-K for the year ended December 31, 2025, and in our Form 10-Q for the quarter ended June 30, 2026. In addition, we may reference measures during today's call, such as EBITDA, adjusted EBITDA, adjusted EBITDA net of NCI and adjusted net income attributable to UHS which are non-GAAP financial measures. Information and reconciliations of these non-GAAP financial measures to net income attributable to UHS can be found in yesterday's press release and under our supplemental materials on our website.
若各位不熟悉此類前瞻性陳述所固有的風險與不確定性,我們建議您仔細閱讀我們截至 2025 年 12 月 31 日止年度 Form 10-K 中「風險因素」及「前瞻性陳述與風險因素」章節,以及截至 2026 年 6 月 30 日止季度 Form 10-Q 中的相關章節。此外,我們在今天的電話會議中可能會提及若干衡量指標,例如 EBITDA、調整後 EBITDA、扣除非控制權益(NCI)之調整後 EBITDA,以及歸屬於 UHS 的調整後淨利,這些均屬非 GAAP 財務衡量指標。這些非 GAAP 財務衡量指標與歸屬於 UHS 的淨利之間的資訊與調節表,可見於昨日的新聞稿,以及我們網站上的補充資料。
With that, let me now turn it over to Marc for some introductory remarks.
接下來,我把時間交給 Marc,請他先做一些開場說明。
Marc Miller - President and Chief Executive Officer
Marc Miller - President and Chief Executive Officer
Thank you, Darren. Good morning, and thank you for joining today's call. I will begin with our key takeaways from the quarter, performance relative to our expectations, the principal operating drivers and progress on our strategic priorities. Before Steve reviews the detailed financial results and our outlook. Overall, underlying performance in the third quarter reflected sequential improvement in several areas.
謝謝你,Darren。各位早安,感謝各位參加今天的電話會議。我將先從本季的重點結論、相對於我們預期的表現、主要營運驅動因素,以及我們在策略優先事項上的進展談起,之後再由 Steve 說明更詳細的財務結果與我們的展望。整體而言,第三季的基本面表現於多個面向呈現逐季改善。
Acute care demand remained favorable. Behavioral health volumes demonstrated an increase relative to recent quarters and labor trends continue to moderate. Expense management remained disciplined overall. Health insurance exchange trends were consistent with our expectations. Steve will provide the reported financial results and segment metrics in his remarks.
急性照護需求仍然維持良好。行為健康(精神健康)服務量相較近期季度有所增加,而勞動力趨勢也持續趨於緩和。整體而言,費用管理仍維持紀律。健康保險交易所(exchange)相關趨勢符合我們的預期。Steve 將在他的發言中提供已揭露的財務結果與各事業部門指標。
Third quarter results included certain items that were not reflected in the outlook we provided with our second quarter results in July. These items included the benefit from the expansion of existing Medicaid supplemental programs in several states, partially offset by other non-recurring litigation and transaction costs, which Steve will take you through in a moment.
第三季結果包含若干項目,這些並未反映在我們於 7 月隨第二季結果所提供的展望中。這些項目包括:多個州既有 Medicaid 補充計畫擴大所帶來的效益,但部分被其他一次性訴訟與交易成本所抵銷;Steve 稍後會為各位進一步說明。
Against that backdrop, I want to highlight three operating and strategic priorities: expanding acute care capacity and outpatient access points, integrating Talkspace, and advancing the recertification process at Laurel Ridge Treatment Center in Texas. First, our recent investments in acute care inpatient capacity helped us meet favorable demand in our markets the additional 177 beds added during the second quarter are expected to continue ramping through year-end. We also expanded our outpatient portfolio by opening one freestanding emergency department in the third quarter and another FED that recently opened during the fourth quarter.
在此背景下,我想強調三項營運與策略優先事項:擴增急性照護量能與門診據點、整合 Talkspace,以及推進德州 Laurel Ridge 治療中心的重新認證流程。第一,我們近期對急性照護住院量能的投資,協助我們滿足各市場的良好需求;第二季新增的 177 張病床預期將持續爬坡至年底。我們也透過擴大門診組合,在第三季新開設一間獨立式急診部(FED),並於第四季近期再開設另一間 FED。
In addition, our ambulatory development pipeline is expected to add several outpatient access points over the coming quarters. The key takeaway is that these investments are performing well, broadening access and supporting growth. We expect their contribution to build over time as the new capacity matures. Second, in behavioral health, we completed the Talkspace acquisition on August 17 and began executing the integration plan. We intend to discuss anticipated synergies in greater detail when we provide 2027 guidance in February.
此外,我們的門診(ambulatory)開發案儲備管線預期將在未來幾季新增數個門診就醫據點。重點結論是:這些投資表現良好,擴大可近性並支持成長。隨著新增量能逐步成熟,我們預期其貢獻將隨時間增加。第二,在行為健康方面,我們已於 8 月 17 日完成 Talkspace 收購,並開始執行整合計畫。我們計畫在 2 月提供 2027 年指引時,更詳細討論預期的綜效。
For the balance of 2026, we are taking a phased approach centered on three integration work streams. The first, deploying a technology platform and tools that enable smoother transitions of care and greater continuity of outpatient care for UHS patients. Number two, establishing referral flow processes to Talkspace from UHS behavioral health and acute care facilities for both individual therapy and medication management services. And three, developing more flexible market-based outpatient offerings, initially emphasizing a virtual intensive outpatient program, or IOP, offering designed to address strong demand in this area. We expect these initiatives to support the acquisition's long-term benefits over the next 12 to 24 months.
在 2026 年剩餘期間,我們採取分階段方式,聚焦於三條整合工作主軸。第一,部署技術平台與工具,使照護轉銜更順暢,並提升 UHS 病患門診照護的連續性。第二,建立從 UHS 行為健康與急性照護機構轉介至 Talkspace 的流程,涵蓋個別治療與用藥管理服務。第三,開發更具彈性的、以市場為基礎的門診服務方案,初期將著重於虛擬密集門診計畫(IOP)服務,以回應此領域強勁需求。我們預期這些措施將在未來 12 至 24 個月支持本次收購的長期效益。
Our priorities are to expand access to outpatient mental health services and strengthen our outpatient growth profile. The key takeaway is that our integration is underway, and the expected benefits will develop in phases as technology, new referral pathways and service offerings are enhanced through our integration efforts. And we'll provide further updates as the integration progresses and the rollout expands across our operations. Third, at Laurel Ridge, our San Antonio team continues to work productively with regulatory authorities and the local community towards recertification, which we currently expect during 2027. The facility's third quarter financial impact was consistent with the assumptions in our updated July outlook.
我們的優先事項是擴大門診心理健康服務的可近性,並強化我們的門診成長輪廓。重點結論是:整合工作已經展開,且隨著技術、新的轉介途徑與服務內容在整合努力下持續強化,預期效益將分階段逐步顯現。隨著整合推進、並在我們的營運體系中擴大導入,我們也將提供進一步更新。第三,關於 Laurel Ridge,我們的聖安東尼奧團隊持續與監管機關及在地社區進行具建設性的合作,以推動重新認證;目前我們預期將於 2027 年完成。該機構第三季的財務影響與我們 7 月更新展望中的假設一致。
In closing, I want to thank the UHS team for its continued dedication to our mission to provide quality care. Our strategy remains consistent, invest in attractive markets, expand access to care, operate efficiently and create long-term value for patients, employees and shareholders. We remain mindful of execution requirements and the ever-evolving operating environment, and we believe the strength of our portfolio, the experience of our management team and underlying demand in our markets continue to position us well over the long term.
最後,我要感謝 UHS 團隊持續投入並致力於我們提供優質照護的使命。我們的策略維持一致:投資於具吸引力的市場、擴大照護可近性、提升營運效率,並為病患、員工與股東創造長期價值。我們也持續留意執行要求與不斷演變的營運環境;我們相信,我們投資組合的實力、管理團隊的經驗,以及各市場的基本需求,將持續使我們在長期上處於有利位置。
With that, I will turn the call over to Steve for additional detail on the quarter.
接下來,我把電話交給 Steve,請他就本季提供更多細節。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Thanks, Marc. I will organize my remarks in four parts. Reported results in unusual items, segment performance, cash flow and capital allocation and our 2026 outlook. Starting with reported results, the company reported adjusted EPS of $5.22 for the third quarter of 2026, representing a decline of 8% year-over-year. Third quarter adjusted EBITDA less NCI was $625 million as compared to $671 million in the third quarter of 2025.
謝謝你,Marc。我將把我的發言分為四個部分:已揭露的結果與特殊項目、各事業部門表現、現金流與資本配置,以及我們對 2026 年的展望。先從已揭露的結果開始,公司 2026 年第三季調整後每股盈餘(adjusted EPS)為 5.22 美元,年減 8%。第三季扣除非控制權益(NCI)之調整後 EBITDA 為 6.25 億美元,相較於 2025 年第三季的 6.71 億美元。
The net out-of-period DPP headwind in the quarter was $37 million when considering amounts recognized for the Washington DC program approved in the third quarter of 2025, netted against out-of-period amounts recognized in this year's third quarter. To distinguish reported results from underlying performance in the third quarter of 2026, three specific items not contemplated in our annual adjusted EBITDA less NCI guidance provided in July produced a net favorable impact of $12 million.
本季跨期(out-of-period)DPP 的淨不利影響為 3,700 萬美元;此係考量 2025 年第三季核准之華盛頓特區計畫所認列的金額,並與本年度第三季所認列的跨期金額相互抵銷後的結果。為了區分 2026 年第三季已揭露結果與基本面表現,有三項在我們 7 月提供的年度「扣除 NCI 之調整後 EBITDA」指引中未納入的特定項目,合計帶來 1,200 萬美元的淨有利影響。
These items were $47 million of supplemental Medicaid benefit, not included in our July forecast, $26 million of additional professional and general liability reserves primarily associated with the tentative settlement of a litigation matter related to our Cumberland facility in Virginia and $8.5 million of transaction-related costs associated with the Talkspace acquisition. Excluding these items, adjusted EBITDA less NCI was below our internal expectations despite modest sequential improvement.
這些項目包括:4,700 萬美元的補充性 Medicaid 福利(未納入我們 7 月的預測)、2,600 萬美元的額外專業責任與一般責任準備金(主要與我們位於維吉尼亞州 Cumberland 設施相關之訴訟案件暫定和解有關),以及 850 萬美元與 Talkspace 收購案相關的交易成本。排除上述項目後,經調整 EBITDA(扣除 NCI)儘管較前一季小幅改善,仍低於我們的內部預期。
The shortfall primarily reflected a slower-than-expected ramp-up at our de novo hospitals and softer-than-expected surgical trends. Turning to segment performance. On a same-facility basis, adjusted admissions in our acute care hospitals increased 4.9% compared with the third quarter of 2025. Volume performance was broad-based geographically and also benefited from capacity additions at three hospitals during the second quarter of 2026. Same-facility acute care emergency department visits increased 4.6%, while same-facility surgeries decreased 0.7% compared with the third quarter of 2025.
落差主要反映我們新設(de novo)醫院的量能爬坡速度低於預期,以及手術趨勢弱於預期。接著說明各事業部門表現。以同院(same-facility)口徑計算,我們急性照護醫院的經調整入院人次較 2025 年第三季增加 4.9%。量的表現於地理分布上相當廣泛,亦受惠於 2026 年第二季三家醫院新增產能。同院急性照護急診就診人次增加 4.6%,而同院手術量較 2025 年第三季下降 0.7%。
Inpatient and outpatient surgical cases declined at similar levels in the quarter. Inpatient medical admissions significantly outpaced surgical admissions, which negatively skewed pricing trends in the quarter. By service line, we experienced strength in cardiology, neurology and urology similar to recent quarters. By payer class, adjusted admissions growth for Medicare and Managed Medicare was above the acute care segment average. Volume growth for Medicaid, managed Medicaid and managed care, excluding exchanges, was positive in the quarter, although below the segment average.
本季住院與門診手術病例數下滑幅度相近。住院內科入院人次顯著超過手術入院人次,導致本季定價趨勢受到不利影響。按服務線別,我們在心臟科、神經科與泌尿科的表現延續近幾季的強勁。按付費方類別,Medicare 與 Managed Medicare 的經調整入院成長高於急性照護事業部平均。本季 Medicaid、managed Medicaid 與 managed care(不含交易所)之量的成長為正,但低於事業部平均。
On a same-facility basis, net revenue in our acute care segment during the third quarter of 2026, increased 4.7%. Excluding the impact of our health plan, same-facility acute care net revenue increased 3.1%. Acute care same-facility revenue per adjusted admission decreased by 1.7% during the third quarter of 2026 on a reported basis and was slightly positive when excluding the net headwind from out-of-period Medicaid supplemental benefits and the shift in exchange to uninsured volumes. We estimate underlying acute care rate growth was approximately 3% and consistent with recent quarters, after adjusting for these factors and normalizing for the higher inpatient medical versus surgical mix. Operating expenses continued to be well managed across labor, supply and other expense categories.
以同院口徑計算,我們 2026 年第三季急性照護事業部淨營收增加 4.7%。若排除我們健康保險計畫的影響,同院急性照護淨營收增加 3.1%。2026 年第三季,按申報口徑計算,同院急性照護每經調整入院之營收下降 1.7%;若排除跨期 Medicaid 補充福利的淨逆風,以及交易所量轉為無保險量的結構性移轉影響,則略為正成長。我們估計,在就上述因素調整並就住院內科相對於手術的較高組合進行常態化後,急性照護的基礎費率成長約為 3%,與近幾季一致。營運費用在人力、耗材及其他費用類別上持續維持良好控管。
Same-facility acute care salaries, wages and benefits expense per adjusted admission increased 2.1% and supply expense for adjusted admission decreased 2.3% over last year third quarter. Other operating expenses increased primarily due to our health plan, which experienced revenue growth of approximately 25% in the third quarter.
同院急性照護每經調整入院之薪資、工資與福利費用較去年第三季增加 2.1%,而每經調整入院之耗材費用下降 2.3%。其他營運費用增加主要來自我們的健康保險計畫,該計畫於第三季的營收成長約 25%。
Same-facility acute care segment EBITDA declined 4.5% in the third quarter of 2026. Excluding the out-of-period supplemental program benefit from both periods, third quarter same-facility Acute Care segment EBITDA increased 2.9%. In our acute care segment, the net out-of-period headwind related to supplemental payments was $29 million comprised of $26 million in the third quarter of 2026 from expanded funding under existing programs, primarily in Washington, DC and California compared with $55 million of out-of-period amounts in the third quarter of 2025 related to the Washington DC program approved last year.
2026 年第三季,同院急性照護事業部 EBITDA 下降 4.5%。若兩期皆排除跨期補充計畫福利,第三季同院急性照護事業部 EBITDA 增加 2.9%。在急性照護事業部中,與補充付款相關的跨期淨逆風為 2,900 萬美元,其中包括 2026 年第三季因既有計畫擴大資金(主要在華盛頓特區與加州)帶來的 2,600 萬美元,相較之下,2025 年第三季則有 5,500 萬美元的跨期金額,係與去年核准的華盛頓特區計畫相關。
For the third quarter of 2026, we estimate that health insurance exchange trends had an impact of slightly less than $25 million which was consistent with the updated outlook provided in July. Exchange volumes declined 17% from the third quarter of 2025, accompanied by a similar increase in the number of self-pay volumes. At Palm Beach Gardens, our acute care de novo hospital remains in the early stages of ramping volumes across multiple service lines.
就 2026 年第三季而言,我們估計健康保險交易所趨勢的影響略低於 2,500 萬美元,與 7 月提供的更新展望一致。交易所量較 2025 年第三季下降 17%,同時自付(self-pay)量出現類似幅度的增加。在 Palm Beach Gardens,我們的急性照護新設(de novo)醫院仍處於多項服務線量能爬坡的早期階段。
Start-up losses improved each month during the third quarter. While the ramp at this facility remains gradual, the progression supports our expectation for continued improvement as we enter Florida seasonally busier winter period. In Washington, DC, Cedar Hill Regional Medical Center operating losses were similar on a sequential basis, excluding supplemental payments.
第三季期間,開辦(start-up)虧損每月皆有所改善。雖然該院爬坡仍屬緩慢,但其進展支持我們的預期:隨著進入佛州季節性較繁忙的冬季期間,表現將持續改善。在華盛頓特區,Cedar Hill Regional Medical Center 的營運虧損若排除補充付款,則按季比較大致相當。
We continue to support the build-out of primary care and specialty physician practices in the community around the hospital and in our MOB. Because these practices remain at varying stages of developing their patient bases within the community, we now expect the hospital to reach operational breakeven in the first half of 2027 compared with our prior expectations of the fourth quarter of 2026. Taken together, Palm Beach Gardens and Cedar Hill are progressing but their pace of maturation remains an important factor in the timing of margin improvement for the Acute Care segment.
我們持續支持醫院周邊社區及我們醫療辦公大樓(MOB)內的基層照護與專科醫師診所建置。由於這些診所在社區內建立病患基礎的進度不一,我們目前預期該院將於 2027 年上半年達到營運損益兩平,較先前預期的 2026 年第四季延後。綜合而言,Palm Beach Gardens 與 Cedar Hill 皆在推進中,但其成熟速度仍是影響急性照護事業部利潤率改善時點的重要因素。
Turning to behavioral health. Third quarter same-facility net revenue increased 4.0% supported by a 2.1% increase in same facility revenue per adjusted patient day and a 2.1% increase in same-facility adjusted patient days. Volumes improved modestly compared with recent quarters, reflecting steady demand and greater emphasis on the continuum of outpatient levels of care. Included in our total behavioral health segment results are Talkspace and an acquisition we completed in our UK operations in July, offset by start-up losses associated with two de novo projects and ongoing operating losses at Laurel Ridge while we work towards recertification.
接著談行為健康(behavioral health)。第三季同院淨營收增加 4.0%,主要受同院每經調整病患日(adjusted patient day)營收增加 2.1%及同院經調整病患日增加 2.1%所支撐。相較近幾季,量的表現小幅改善,反映需求穩健,且我們更著重於門診照護層級的連續性(continuum)。我們行為健康事業部的整體結果包含 Talkspace,以及我們於 7 月在英國營運完成的一項收購;上述貢獻部分被兩個新設(de novo)專案的開辦虧損,以及 Laurel Ridge 在我們推動重新認證(recertification)期間持續的營運虧損所抵銷。
Given the mid-quarter closing, Talkspace's contribution to third quarter earnings was immaterial. In our behavioral health segment, the net out-of-period headwind related to supplemental payments was approximately $8 million in the third quarter of 2026, due primarily to the new Washington DC program benefit in the third quarter of 2025. For the third quarter of 2026, behavioral health segment, same-facility salaries, wages and benefits per adjusted patient day increased 3.6% over the prior year, improving further on a sequential basis due to continued moderation in head count growth.
由於於季中完成交割,Talkspace 對第三季獲利的貢獻不具重大性。在行為健康事業部中,與補充付款相關的跨期淨逆風於 2026 年第三季約為 800 萬美元,主要係因 2025 年第三季新增的華盛頓特區計畫福利所致。就 2026 年第三季而言,行為健康事業部同院每經調整病患日之薪資、工資與福利較前一年增加 3.6%,且由於人力編制成長持續趨緩,按季比較進一步改善。
Turning to cash flow and capital allocation. Third quarter cash generated from operating activities was $637 million compared with $381 million during the same period last year. During the third quarter of 2026, we spent $214 million on capital expenditures, and we anticipate capital expenditures to be slightly below $1 billion for the full year of 2026. The as several large acute care de novo and expansion projects are now completed, we expect capital expenditures to moderate towards $800 million beyond 2026.
接著談現金流與資本配置。第三季營運活動產生的現金為 6.37 億美元,去年同期為 3.81 億美元。2026 年第三季,我們資本支出為 2.14 億美元;我們預期 2026 全年資本支出將略低於 10 億美元。隨著數個大型急性照護新設與擴建專案現已完工,我們預期 2026 年之後資本支出將趨於緩和,朝 8 億美元水準回落。
During the third quarter of 2026, we acquired $1.35 million of our own shares at a total cost of $242 million, bringing year-to-date share repurchases to a total of $690 million. As of September 30, 2026, we had $735 million repurchase authorization available pursuant to our stock buyback program, and we expect to remain active with share repurchase for the foreseeable future.
2026 年第三季,我們以總成本 2.42 億美元回購自家股票 135 萬股,使得年初至今的股票回購總額達 6.90 億美元。截至 2026 年 9 月 30 日,依據我們的庫藏股回購計畫,尚有 7.35 億美元的回購授權額度可用,我們預期在可預見的未來仍將持續積極進行股票回購。
From a balance sheet perspective, we ended the quarter with cash of $169 million, total debt of $5.7 billion, an average of 2.17 times. Total debt reflects the August refinancing of our September 2026 debt maturity and incremental borrowings associated with the Talkspace acquisition. As of September 30, 2026, we had approximately $1.2 billion of additional borrowing capacity available pursuant to our revolving credit facility. We remain committed to maintaining leverage within our target range of 2 to 3 times.
就資產負債表而言,本季期末現金為 1.69 億美元,總負債為 57 億美元,平均槓桿倍數為 2.17 倍。總負債反映我們於 8 月就 2026 年 9 月到期債務進行再融資,以及與 Talkspace 收購案相關的額外借款。截至 2026 年 9 月 30 日,依據我們的循環信用融資額度(revolving credit facility),尚有約 12 億美元的額外借款能力可用。我們仍致力於將槓桿維持在目標區間 2 至 3 倍之內。
Finally, turning to our 2026 outlook. We are reiterating the financial and operating forecast ranges issued with our second quarter results in July. Based on year-to-date trends through the third quarter and the ongoing ramp of our acute care hospitals in Washington, DC and Palm Beach Gardens, Florida, we currently expect results to be towards the lower end of these ranges. The reiterated ranges reflect continued underlying operating improvement balanced against the pace of de novo facility ramp-ups and the other near-term variables discussed today.
最後,談到我們對 2026 年的展望。我們重申在 7 月公布第二季業績時所提供的財務與營運預測區間。根據截至第三季的年初至今趨勢,以及我們位於華盛頓特區與佛羅里達州棕櫚灘花園(Palm Beach Gardens)的急性照護醫院持續爬坡的情況,我們目前預期結果將落在這些區間的較低端。此次重申的區間反映:在持續的基礎營運改善之下,仍需與新設(de novo)設施爬坡速度及今日所討論的其他短期變數相互平衡。
Operator, that concludes our prepared remarks and we'd be pleased to answer questions at this time.
接線員,我們的準備發言到此結束,接下來很樂意回答問題。
Operator
Operator
(Operator Instructions)
(接線員指示)
AJ Rice, UBS.
UBS 的 AJ Rice。
AJ Rice - Analyst
AJ Rice - Analyst
Thanks. Hi, everybody. Just -- I know it's early and to be talking about '27, but some of the companies are. So I'll ask it a view. At least how do you think about puts and takes for next year? I guess, specifically, I'm going to ask you on EPP headwinds, supplemental payment headwinds next year given some out-of-period recognition this year. and early thoughts on incremental public exchange headwind, if any.
謝謝。各位好。只是——我知道現在談到 27 年還早,但有些公司已經在談了。所以我也想問一下你們的看法。至少你們如何看待明年的利多與利空因素?我想更具體地問:明年 EPP 的逆風、以及因今年有部分跨期認列而導致明年補充性支付(supplemental payment)的逆風,你們怎麼看?另外,也想聽聽對公共交易所(public exchange)額外逆風(若有)的初步想法。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So I would just remind everybody, AJ, that consistent with prior years, we plan to issue our full comprehensive 2027 guidance in February when we report our fourth quarter results. We feel good about the core elements of our 2026 growth algorithm guidance in both segments, which we went through last quarter.
好的。AJ,我先提醒大家,與往年一致,我們計畫在 2 月公布第四季業績時,提供完整且全面的 2027 年指引。我們對 2026 年兩大事業部的成長演算法(growth algorithm)指引之核心要素感到樂觀,這部分我們在上季已經說明過。
Outside of that, we can point to a few items, a couple of which you mentioned, in terms of material headwinds and tailwinds as we begin to think about 2027. The biggest swing factors, I think, in 2027, relate to improvements at facilities that are incurring operating losses during 2026, particularly the Laurel Ridge San Antonio facility that we talked about and the two acute care de novos that we mentioned in our prepared remarks.
除此之外,當我們開始思考 2027 年時,仍可指出幾個重要的逆風與順風因素,其中有幾項正如你提到的。我認為 2027 年最大的波動因素,與 2026 年仍在承受營運虧損的設施之改善有關,特別是我們提到的聖安東尼奧(San Antonio)Laurel Ridge 設施,以及我們在準備發言中提到的兩家新設(de novo)急性照護醫院。
Cumulatively, these facilities are expected to contribute operating losses of $80 million to $100 million in 2026, and we believe there is potential to recover at least a meaningful portion of those losses in 2027 as we anticipate making further operational progress at the de novo facilities over the next several quarters and regaining certification at the San Antonio facility. As it relates to San Antonio, I would just note, we're making progress towards recertification and remain confident that we'll achieve that in 2027, giving us a path to rebuild census in a deliberate manner.
合計而言,預期這些設施在 2026 年將造成 8,000 萬至 1 億美元的營運虧損;我們認為在 2027 年有機會收復其中至少相當可觀的一部分,因為我們預期未來幾季新設設施的營運將持續進展,且聖安東尼奧設施可望重新取得認證。就聖安東尼奧而言,我補充一下:我們正朝重新認證取得進展,並仍有信心在 2027 年達成,讓我們能以審慎的方式重建住院人數(census)。
On the headwind side, and I think you mentioned a couple of these things, the biggest swing factors relate to regulatory changes that continue to play out in the operating environment, particularly the impact from the exchanges the potential impact of Medicaid work requirements and the initial impact of reduction to Medicaid supplemental funding. We also had a material amount of prior year DPP benefit in calendar year '26 that will not repeat in 2027. As it relates to Medicaid supplemental payments, we estimate the 2027 headwind will be approximately $175 million to $200 million.
在逆風方面——我想你也提到其中幾項——最大的波動因素與持續在營運環境中發酵的監管變化有關,尤其是交易所(exchanges)的影響、Medicaid 工作要求的潛在影響,以及 Medicaid 補充性資金(supplemental funding)削減的初期影響。此外,我們在 2026 日曆年度有相當可觀的前一年度 DPP 利益,這在 2027 年不會重複出現。就 Medicaid 補充性支付而言,我們估計 2027 年的逆風約為 1.75 億至 2 億美元。
This primarily includes prior year amounts that we recorded in '26 for DPP programs in Florida, Nevada, io, California and Washington, DC as well as approximately $10 million of impact during the fourth quarter 2027 from the initial provider tax portion of the OB3 funding cuts. As it relates to the exchanges, annualizing the second half 2026 run rate would create a $15 million headwind in 2027. Further changes in exchange enrollment could increase that number and we'll have greater insight into that following the open enrollment period. As it relates to Medicaid work requirements, it's difficult to provide an estimate on the potential impact because the implementation timing may lag up to six months in certain states.
這主要包含我們在 26 年針對佛羅里達、內華達、愛荷華、加州與華盛頓特區的 DPP 計畫所入帳的前一年度金額,以及 2027 年第四季因 OB3 資金削減中「初始提供者稅(provider tax)部分」所帶來約 1,000 萬美元的影響。就交易所而言,若將 2026 年下半年的運行水準年化,將在 2027 年形成 1,500 萬美元的逆風。若交易所投保人數(enrollment)進一步變動,該數字可能增加;在開放投保期(open enrollment period)結束後,我們會有更清楚的掌握。至於 Medicaid 工作要求,由於部分州的實施時點可能延後最多六個月,因此很難就其潛在影響提供估算。
More importantly, the state specific regulatory guidance related to the medical frailty exceptions remains a key open item. Our baseline assumption is that the impact of Medicaid work requirements will be primarily concentrated in Medicaid expansion states and that a vast majority of behavioral health patients and a meaningful portion of our acute care patients could be exempt from work requirements because their diagnoses meet the medical frailty exemption.
更重要的是,各州針對「醫療脆弱(medical frailty)」豁免的州別監管指引,仍是關鍵且尚未定案的事項。我們的基準假設是:Medicaid 工作要求的影響將主要集中在 Medicaid 擴張州(expansion states);而絕大多數行為健康(behavioral health)病患,以及我們急性照護病患中相當一部分,可能因其診斷符合醫療脆弱豁免,而可免於工作要求。
As investors develop estimates on work requirements, it's worth noting from a volume perspective, Medicaid volumes and expansion states represented approximately 15% of our total acute care segment adjusted admissions and 30% of total behavioral health segment patient days. Broadly, I think as most investors know, Medicaid revenue per unit of volume is lower than other payers. So as you do those calculations, you should keep those in mind.
當投資人建立對工作要求的估算時,從量的角度值得注意的是:在 Medicaid 擴張州,Medicaid 量約占我們急性照護事業部調整後入院人次(adjusted admissions)的約 15%,以及行為健康事業部總病患日(patient days)的 30%。整體而言,我想多數投資人都知道,Medicaid 每單位量的收入低於其他付款方。因此在進行相關計算時,請將這點納入考量。
AJ Rice - Analyst
AJ Rice - Analyst
That's very helpful. Thanks for that. Maybe just a follow-up. You've had very strong volumes. Obviously, it's been a shift. It looks like to medical from surgical. I wondered if you could drill down just and talk a little bit about service lines, what's been strong on the medical side? And are you attributing the softness in surgery mainly to public exchange disenrollment or economy or something else?
這非常有幫助。謝謝你的說明。我再追問一下。你們的量一直非常強勁。顯然也出現了結構性轉變。看起來是從外科轉向內科。我想請你們更深入談談服務線(service lines):內科端有哪些表現特別強?另外,外科走弱你們主要歸因於公共交易所退保(disenrollment)、景氣,或其他因素?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. I think from our perspective, AJ, the trend towards a slightly weaker surgical mix is an acceleration of existing trends that we've seen for some time. And that is the continued shift of procedures, both in and outpatient procedures out of the hospital in and outpatient services and into alternative settings, whether they are ASCs or physician offices, and you really see this in particular in certain service lines. So GI, as an example, and we've seen just an accelerated shift of procedures within an outpatient into alternative settings and out of the hospital. A number of orthopedic procedures as well.
好的。AJ,就我們的觀點而言,外科組合(surgical mix)略為走弱的趨勢,是我們一段時間以來所見既有趨勢的加速。也就是各類手術——不論住院或門診——持續從醫院端的住院與門診服務,轉移到其他替代場域,無論是門診手術中心(ASC)或醫師診所;而你在某些服務線上會特別明顯地看到這點。例如腸胃科(GI),我們看到門診端的處置加速轉移到替代場域、離開醫院。另外也包括多項骨科處置。
We mentioned in our prepared remarks some of the service lines that have been performing fairly robustly, that those included cardiology, neurology and urology. But yes, I think, again, in our minds, what we're just seeing is this accelerated shift of procedures into these alternative settings.
我們在準備發言中也提到一些表現相當強勁的服務線,包括心臟科、神經科與泌尿科。但沒錯,我想我們看到的,仍是處置加速轉移到這些替代場域的趨勢。
Operator
Operator
Ann Hynes, Mizuho.
Mizuho 的 Ann Hynes。
Ann Hynes - Analyst
Ann Hynes - Analyst
Great. Thank you. Just the two acute facilities that are not ramping as you thought? What's driving that slower ramp? Is there anything structural or challenges that you face. I've been covering the company for a long time, and I don't remember a time where like the new acute care hospitals are ramping below expectations. So if you can just go into each market, and what's driving the loss versus your expectations? That would be great. Thank you.
很好。謝謝。關於那兩家爬坡速度不如你們預期的急性照護設施:是什麼原因造成爬坡較慢?背後的驅動因素是什麼?是否有任何結構性因素或你們面臨的挑戰?我長期追蹤這家公司,印象中很少看到新的急性照護醫院爬坡低於預期。所以如果你們能分別就各個市場說明,究竟是什麼導致虧損高於你們的預期,那就太好了。謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So I'll address Cedar Hill first. Cedar Hill in Washington, DC opened in April of 2025. And I think as we've been commenting consistently since that opening, it opened with a busy emergency room activity and emergency room activity has remained busy since its opening.
好的。我先談 Cedar Hill。位於華盛頓特區的 Cedar Hill 於 2025 年 4 月開業。我想正如我們自開業以來持續評論的那樣,它在開業時急診室(ER)就非常繁忙,而且自開業以來急診室的量一直維持在繁忙水準。
But what has lagged has been a busier surgical and procedural schedule. And I think the reason for that primarily is a lack of physician infrastructure in that part of the Washington, D.C. market for years, and this is for those of you who are familiar with Washington, D.C. and Ward 7 and 8, there was really a lack of quality health care and nations were leaving Ward 7, 8 to get their health care elsewhere in the city. And as a consequence, doctors really were not locating in Ward 7 and 8, doctor offices were not.
但相對落後的是外科與處置類手術排程變得更為繁忙。我認為主要原因是多年來在華盛頓特區市場的那一區域缺乏醫師端的基礎設施;對於熟悉華盛頓特區以及第7、8選區(Ward 7 and 8)的人來說,當地確實缺乏優質醫療,居民不得不到市內其他地區就醫。因此,醫師其實不太會選擇在第7、8選區設點,診所也沒有。
And as we indicated in our prepared remarks, we've addressed that by working with a number of different physicians and physician groups to establish practices in Ward 7 and 8 -- within Ward 7 and 8 in the MOB adjacent to our hospital, et cetera. But those practices are relocating and they're developing, but they're in different stages of development. And that takes some time. And I think that's been the major issue in terms of the timing of the development of Cedar Hill. Structurally, I think we believe that all the things that we thought about what would make this hospital successful are still there and will do so just taking somewhat longer.
正如我們在事先準備的發言中所提到的,我們已透過與多位醫師及醫師團體合作來解決這個問題,在第7、8選區內—例如在我們醫院旁的醫療辦公大樓(MOB)等—設立診所。但這些診所正在遷入並逐步發展,而且各自處於不同的發展階段。這需要一些時間。我認為這一直是Cedar Hill發展時程上的主要問題。從結構面來看,我們相信先前所設想、能讓這家醫院成功的所有要素仍然存在,也會發揮作用,只是需要比原先預期更長的時間。
The other nuance comment that I'll make, and I think I made it last quarter as well as it relates to Cedar Hill is that the arrangement we had with the district in entering the Cedar Hill partnership with the district was that they would build and essentially finance the construction of Cedar Hill. So the absolute amounts of earnings, the absolute margins that we're going to have to achieve at Cedar Hill to get to our sort of target rates of return will be less than in those hospitals where we built and invested the hundreds of millions of dollars to build the hospital.
另外我想補充一點細節,我想我上季也提過,關於Cedar Hill:我們與特區政府(district)在建立Cedar Hill合作夥伴關係時的安排是,由他們興建並基本上負責融資Cedar Hill的建設。因此,為了達到我們目標報酬率,Cedar Hill需要達成的絕對獲利金額、絕對利潤率,會低於那些由我們自行興建、投入數億美元資本建院的醫院。
As far as the facility in Palm Beach Gardens goes, I think that, honestly, one of the biggest challenges we had at its opening was that we opened in the beginning of the summer which is a difficult time to open, as you might imagine, in South Florida. It was not our original intent. We had originally planned to open earlier and take advantage of the busy season in Florida, but construction delays sort of made that impossible.
至於Palm Beach Gardens的設施,我認為坦白說,我們在開幕時面臨的最大挑戰之一,是我們在初夏開幕;如你所想,在南佛州這是一個不太理想的開幕時點。這並非我們原本的計畫。我們原先規劃更早開幕,以把握佛州的旺季,但施工延誤使得這變得不可能。
So I think by opening in the summertime, we got off to a bit of a slower start, but expect the facility. And I think, again, in our prepared comments, we indicated the facility's getting better. Volumes are increasing every month. and we expect that to accelerate as the busy season sort of ramps up in Florida over the next several months. I'll reiterate the same comment. No structurally, I think everything believed about the potential success of that hospital is still consistent with our original views, just taking a little bit longer to ramp up than we originally anticipated.
因此我認為在夏季開幕讓我們起步稍慢一些,但我們對該設施仍有期待。而且我想我們在事先準備的發言中也提到,該設施的表現正在改善。量能每個月都在增加。我們預期,隨著未來幾個月佛州旺季逐步升溫,這個增速會加快。我再重申同樣的看法。從結構面來看,我們對那家醫院成功潛力的所有判斷仍與原先觀點一致,只是爬坡速度比我們最初預期稍慢。
Ann Hynes - Analyst
Ann Hynes - Analyst
Thanks.
謝謝。
Operator
Operator
Justin Lake, Wolfe Research.
Justin Lake,Wolfe Research。
Justin Lake - Analyst
Justin Lake - Analyst
Thanks. Good morning. Just a couple of numbers questions here. Steve, maybe you can break down the $80 million to $100 million of losses between those three facilities. And Laurel Ridge in particular, what were the operating profits there when it was open, so we can get what it could recover to? And maybe Marc can give any time line he thinks within 2027 when you're thinking that might that might come back online? Thanks.
謝謝。早安。這裡有幾個數字方面的問題。Steve,也許你可以拆解一下那三個設施合計8,000萬到1億美元的虧損。另外,Laurel Ridge特別是,它在停業前的營運利潤是多少,讓我們可以了解它可能恢復到什麼水準?以及Marc是否可以提供你認為在2027年內大概什麼時點可能重新上線的時間表?謝謝。
Marc Miller - President and Chief Executive Officer
Marc Miller - President and Chief Executive Officer
Yeah. I mean we're confident that we're going to be back online sooner than later, but we don't have an exact date in 2027. We're still working with all the regulatory agencies. Things are going well. That will be back to where we were, we expect in 2027, but I can't give you an exact date.
是的。我們有信心會在不久後重新上線,但目前沒有2027年的確切日期。我們仍在與所有監管機構合作。進展良好。我們預期在2027年會回到原先的狀態,但我無法給你一個確切日期。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
And as far as the numbers go, Justin, when we first announced the loss of certification at Laurel Ridge, we disclosed that last year the pretax income at that facility was in the $20 million, $25 million range. We've talked about incurring since it has lost it's certification, but has continued to treat a small number of patients that we expect it will lose $5 million or $10 million a quarter each quarter that we remain open without certification.
至於數字方面,Justin,當我們首次宣布Laurel Ridge失去認證時,我們揭露該設施去年稅前盈餘約在2,000萬到2,500萬美元區間。我們也談到,自從失去認證後,雖然仍持續收治少量病患,但我們預期在未取得認證而仍維持開放的每一季,都會每季虧損500萬到1,000萬美元。
We've talked about Cedar Hill over the last several quarters, losing roughly $10 million a quarter. And as far as the Palm Beach Gardens Hospital, you can pretty much get that from looking at the difference between our same-store acute results and our full acute care results, but we lost about $15 million in this quarter, expect to improve a little bit in Q4 and then continue to improve gradually from there.
我們在過去幾季也談到Cedar Hill,每季大約虧損1,000萬美元。至於Palm Beach Gardens Hospital,你大致可以從我們同店急性照護(same-store acute)結果與整體急性照護(full acute care)結果的差異看出來;本季我們約虧損1,500萬美元,預期在第四季會小幅改善,之後再逐步改善。
Operator
Operator
Matthew Gillmor, KeyBanc.
Matthew Gillmor,KeyBanc。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
Hey, thanks for the question. You called out labor as a positive factor in the quarter. I was hoping you could elaborate on what you're seeing in terms of wage growth or turnover or use of contract labor.
嗨,謝謝讓我提問。你提到本季勞動力是正向因素。我想請你更詳細說明你們在薪資成長、離職率或合約人力使用方面看到的情況。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So I think a little bit different story in the two segments. I think in the behavioral segment, we talked over the course of several quarters that we had sort of invested in -- I'm going to describe it as outsized account growth. because we've discussed, I think, for quite some time that in some of our behavioral facilities and markets, we were -- our volume growth was muted because of a constraint in staffing, not enough nurses or therapists or the non-professional techs that are important to care in the behavioral segment. But we accomplished that, I think head count growth has continued to decelerate.
好的。我認為兩個事業部門的情況有些不同。在行為健康(behavioral)部門,我們在過去幾季提到,我們做了一些投入——我會形容為超出常態的人力編制成長。因為如我們討論已久,在部分行為健康設施與市場,我們的量能成長受到抑制,原因是人力配置受限:護理師、治療師或在行為健康照護中很重要的非專業技術人員不足。但我們已經達成改善,我認為人數(head count)成長已持續放緩。
It decelerated in the third quarter. I think it rose by about 1.5%. And I think going forward, head count growth in the behavioral segment will largely be aligned with volume growth. So that's been a benefit and an improvement in the Behavioral Health segment.
第三季確實放緩了。我認為約成長了1.5%。而展望未來,行為健康部門的人數成長大致會與量能成長一致。因此,這對行為健康部門而言是一項助益與改善。
I think in the acute segment, as your question sort of alluded to, our -- we've seen a fairly significant reduction in temporary and traveling labor I think that has risen in the most recent quarter by 3%. So it is well controlled. And wage inflation has certainly come down from its heights during the pandemic to something in the 3%, 3.5% range in both segments.
我認為在急性照護(acute)部門,正如你的問題所暗示的,我們看到臨時與差旅人力(temporary and traveling labor)有相當顯著的下降;我想在最近一季這項成本上升了3%。所以整體控制得很好。而薪資通膨也確實已從疫情期間的高點回落,在兩個部門都落在約3%到3.5%的區間。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
Got it. And then if I could follow up on the Talkspace acquisition. It sounds like you'll share more on the fourth quarter call about the integration and synergy opportunity. I wanted to see if you'd be willing to discuss will there be synergies that you think you'd be able pull through during the 2027 period? Or is that a longer-term priority?
了解。另外我想追問Talkspace收購案。聽起來你們會在第四季電話會議分享更多整合與協同效益的機會。我想確認你是否願意談談:你認為在2027年期間能夠實現的協同效益會有哪些?還是那會是更長期的優先事項?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
So what we said originally, Matt, when we disclosed the Talkspace acquisition is that our expectation in the first 12 months of ownership, which would be into the third quarter of next year, was that the transaction would be slightly accretive. There's a very small amount of overhead and cost savings sort of duplicative cost savings as we combine two public companies. But the vast majority of synergies are revenue synergies. And the opportunity that combining the lower acuity population -- patient population that Talkspace has and the higher acuity patient population that UHS has really creates this robust continuum of care that really doesn't exist anywhere else in the behavioral space. And that's the opportunity.
所以我們最初在披露收購 Talkspace 時所說的,Matt,是我們預期在持有的前 12 個月(也就是到明年第三季),這筆交易將會略具增益(slightly accretive)。隨著我們把兩家上市公司整合在一起,會有非常少量的管理費用與成本節省,屬於某種重複性成本的節省。但絕大多數的綜效是營收綜效。把 Talkspace 的較低急性度族群——病患族群——與 UHS 的較高急性度病患族群結合起來,確實能打造一個在行為健康領域其他地方幾乎不存在的、非常強健的照護連續體。而這就是機會所在。
As far as the timing of it, I think we'll begin to realize that, and we said this in our prepared remarks in the first 12 to 24 months of ownership. So beginning in the back half of next year. And as we, I think, noted in our remarks, I think we'll be more specific about that and how much of that we've included in our guidance when we when we present guidance in February. But as Marc indicated in his remarks, we're certainly beginning to focus on those revenue synergies and create all the changes in policies and procedures and infrastructure and technology that we'll need to execute on those synergies next year.
至於時程方面,我認為我們會開始實現這些成果,而且我們在事先準備的講稿中也提到,會在持有後的前 12 到 24 個月內逐步體現。也就是從明年下半年開始。另外,正如我們在發言中提到的,我想我們會在 2 月提出指引時,更具體說明這點,以及我們在指引中納入了多少。但如 Marc 在他的發言中所指出的,我們確實已開始聚焦於這些營收綜效,並建立明年執行這些綜效所需的政策與流程、基礎設施與科技等各項變更。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
Great. Thank you.
很好。謝謝。
Operator
Operator
Stephen Baxter, Wells Fargo.
Wells Fargo 的 Stephen Baxter。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
Hi. Thanks. I wanted to ask about the same-store acute revenue per adjusted issue in the quarter. How should we think about what that figure would be if we were to exclude all change in year-over-year Medicaid supplemental, I guess not just the out-of-period components. I guess how did that compare to your expectations? And how much of a pressure is the surgical decline putting on those metrics? Thanks.
嗨,謝謝。我想問一下本季同店(same-store)的急性照護每調整後入院(adjusted admission)收入。如果我們把年對年 Medicaid 補充款項(supplemental)的所有變動都排除掉——我想不只是跨期(out-of-period)的部分——那個數字應該怎麼看?我想問的是,這和你們的預期相比如何?另外,手術量下滑對這些指標造成多大壓力?謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So again, in the remarks, I think we called out three items that I think are putting pressure on that revenue per adjusted admission metric in the quarter. And I think you tick through them. One is the impact of the exchanges, while that's playing out, I think, consistent with our expectations, it's certainly a drag compared to last year. Then there's the out-of-period DPP which we talked about and then the Med-Surg mix pressure, which we talked about.
好的。所以再說一次,我想我們在發言中點出了三個項目,我認為它們在本季對每調整後入院收入這個指標造成壓力。我想你可以逐一看過。第一個是交易所(exchanges)的影響;在這個情況持續發展的同時,我認為它符合我們的預期,但相較去年確實是一個拖累。接著是我們談到的跨期 DPP。
We think the Med-Surg mix pressure probably reduces the growth in revenue per adjusted admission by about 100 basis points. We think if we adjust for all 3 of those items revenue per admission would have been up in the 3% range, which is within the range that we've talked about as the sustainable going forward range for pricing.
我們認為內外科組合壓力大概會使每調整後入院收入的成長率降低約 100 個基點。我們認為如果把這三項因素都調整掉,每入院收入本來會有約 3% 左右的成長,這也落在我們所談到、未來可持續的定價區間之內。
Stephen Baxter - Analyst
Stephen Baxter - Analyst
Okay. When you look at the improvement in acute volumes that you saw in the quarter, is there any meaningful difference in either like geographic strength or different payer strengths you want to call out?
了解。當你們看本季急性照護量的改善時,在地理區域的強弱,或不同付款方(payer)的強弱方面,有沒有什麼顯著差異值得特別提出?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
I think it's pretty broad-based geographically. We talked a little bit about payer mix in our remarks. I think Medicare is growing faster than the divisional average, Medicaid and commercial is growing a little bit -- are both positive but growing a little bit slower than the divisional average. And we've seen an increase in self-pay or on compensated care largely sort of a one-for-one swap in the decline for exchanges. I think the only other geographic note I would make and it's probably more a fourth quarter note is that last year, we had a pretty soft fourth quarter in the Vegas market.
我認為在地理上相當廣泛。我們在發言中也稍微談到付款方組合。我認為 Medicare 的成長快於事業部平均;Medicaid 與商業保險也都是正成長,但成長速度略低於事業部平均。而我們看到自費(self-pay)或補償性照護(compensated care)有所增加,基本上大致是一對一對應交易所(exchanges)下滑的部分。我想我唯一會補充的地理面觀察——而且可能更偏向第四季的觀察——是去年拉斯維加斯市場第四季相當疲弱。
They had a very light flu season in a year in which almost everybody else had a pretty acute flu season. So I think we're thinking about that as a bit of a tailwind for us in the fourth quarter. But otherwise, the strength in acute volumes has been pretty broad geographically.
那裡的流感季非常輕微,而在那一年幾乎其他所有地方的流感季都相當嚴重。所以我們認為這在第四季對我們會是一點順風。但除此之外,急性照護量的強勁表現,在地理上是相當廣泛的。
Operator
Operator
Kevin Fischbeck, BOA.
BOA 的 Kevin Fischbeck。
Kevin Fischbeck - Analyst
Kevin Fischbeck - Analyst
Great. Thanks. I want to go back to your answer about the surgical volume coming in a little bit lower than what you guys were thinking about and kind of attributing that to an acceleration of recent trends. What would you attribute that acceleration to though? Is there something specific? Is it the IPO? Or is it something else. I'm just trying to figure out how long this acceleration might last and would be better to understand what's causing it.
很好。謝謝。我想回到你們剛才對手術量比你們原先預期略低的回答,你們把它歸因於近期趨勢的加速。但你們會把這個加速歸因於什麼呢?有沒有什麼特定原因?是 IPO 嗎?還是其他因素?我只是想判斷這種加速可能會持續多久,也希望更了解背後的原因。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
So first, Kevin, I would say I don't think it's the inpatient-only dynamic. When we looked at the procedures covered by the inpatient-only regs, I think we concluded that most of our procedures that fall into that those categories were procedures that had more than a two midnight stay and appeared to us to be more acute than would allow them to really be transferred or evolved into outpatient procedures.
所以首先,Kevin,我會說我不認為這是「僅限住院」(inpatient-only)的動態所致。當我們檢視那些受僅限住院規範(inpatient-only regs)涵蓋的手術時,我想我們的結論是:我們大多數落在那些類別中的手術,住院天數通常超過兩個午夜(two midnight stay),而且在我們看來急性度更高,因此不太可能被轉移或演變成門診手術。
Yeah, I don't know that I have a great explanation for exactly why we -- and I think the industry in general has seen this acceleration in certain procedures to outpatient. But I'll describe one of the challenges we see, and I'll use GI as an example, is that as more and more GI procedures are being done outside of the hospital and largely in physician offices and in ASCs. We have found it difficult even to get GIs to cover our emergency rooms.
是的,我不確定我能否對我們——以及我認為整個產業——在某些手術加速轉向門診這件事,給出一個非常好的、精確的解釋。但我可以描述我們看到的一個挑戰,我用腸胃科(GI)作為例子:隨著越來越多 GI 手術在醫院外進行,而且主要是在醫師診所與門診手術中心(ASCs)進行,我們發現甚至很難讓腸胃科醫師來支援我們的急診室。
We either can't get them to do it at all or the expense of doing it and the cost of doing it is really sort of outsized. And so as a consequence, in some of our facilities, even our emergency room visits that are GI-related are being diverted to someplace else because we just don't have the coverage. So I think there's a bit of a sort of compounding effect that as more and more of these procedures, elective procedures move into outpatient settings in some of these areas. And again, I think GI sort of stands out for us. even the emergency procedures that would have traditionally come to our emergency rooms are being diverted elsewhere.
我們要嘛完全找不到他們來做,要嘛即使能做,其費用與成本也明顯偏高、比例失衡。因此,在我們某些院所,甚至連與 GI 相關的急診就診也會被轉送到其他地方,因為我們就是沒有足夠的支援覆蓋(coverage)。所以我認為存在某種疊加效應:當這些領域中越來越多的選擇性手術(elective procedures)移到門診場域。再說一次,我們覺得 GI 對我們而言特別明顯。就連過去傳統上會到我們急診室的緊急處置,也正在被轉往其他地方。
Kevin Fischbeck - Analyst
Kevin Fischbeck - Analyst
Okay. Great. And then, I guess, one of the -- I guess, the tailwinds that you mentioned in 2027, you just said the long-term growth algorithm. Can you just remind us that -- I know that like this year, you're looking for 4.5% to 6.5% on the acute and 3% to 5% on behavioral. Is that what you're talking about? Or are you talking about something a little bit different.
了解,很好。另外,我想你們提到 2027 年的一個——我想是你們提到的順風因素——你剛剛說的是長期成長算法(long-term growth algorithm)。你能不能提醒我們一下——我知道今年你們對急性照護的目標是 4.5% 到 6.5%,對行為健康是 3% 到 5%。你說的是這個嗎?還是你指的是有點不同的東西?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
No. I think in last quarter, we sort of laid out our growth algorithms for the two segments in acute care. We're talking about 1.5% to 2.5% adjusted admission growth. for the year, I think we're averaging slightly above that, I think 2.6% for the year and then 2% to 3% pricing growth. As I mentioned in my previous response, we believe you sort of adjust for all these exogenous factors, we're running at around that 3% in the quarter, so at the low end of that range.
不是。我想在上個季度,我們已經大致說明了兩個事業部門的成長算法;在急性照護方面,我們談的是調整後入院量成長 1.5% 到 2.5%。就今年而言,我想我們的平均略高於那個區間,大概是 2.6%,然後定價成長是 2% 到 3%。如我在前一個回覆中提到的,我們認為如果把這些外生因素都調整掉,本季大約是在 3% 左右,也就是落在該區間的低端。
On the behavioral side, we modified our growth algorithm, our adjusted patient day growth algorithm to 1% to 2% last quarter. And I think we're running for the year in the 1.7% range, so kind of towards the higher end of that range. and then 2% to 3% pricing in behavioral, and I think we run within that range in behavioral as well.
在行為健康(behavioral)方面,我們調整了成長演算法,也就是我們調整後的病人日(patient day)成長演算法,上季設定為1%到2%。我認為今年目前大約在1.7%的區間,因此算是偏向該區間的高端。另外,行為健康的定價為2%到3%,我認為我們在行為健康的定價也同樣落在這個區間內。
Operator
Operator
Craig Hettenbach, Morgan Stanley.
Craig Hettenbach,摩根士丹利。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Yes, thank you. Just following up on Talkspace and understanding it's recently closed. But if you can just give some context of how that business is performing, kind of growth rates you expect. And then as a follow-up on that, you mentioned kind of the unique offering across Mental Health, how are you thinking about that in terms of implications of payer relationships on a longer-term basis as this strategy unfolds.
是的,謝謝。我想追問一下Talkspace,並了解它最近已完成交割。但如果可以的話,請提供一些該業務目前表現的背景資訊,以及你們預期的成長率大概如何。另外作為延伸追問,你提到在心理健康(Mental Health)領域具備某種獨特的產品/服務組合;隨著這項策略推進,你們如何看待其對付款方(payer)關係在較長期層面的影響?
Marc Miller - President and Chief Executive Officer
Marc Miller - President and Chief Executive Officer
So this is Marc. As we're integrating Talkspace, I mean one of the big things when we talk about the continuum Talkspace was acquiring patients in a distinct way, having nothing to do with patients coming from other behavioral health settings, primarily. That opportunity now exists for us to send patients, refer patients over to Talkspace who are already in our ecosystem, whether in our outpatient things or in our inpatient settings. Conversely, we have an opportunity now, and we're just starting to see this where there are patients that are in that Talkspace ecosystem that if they need further care, a higher level of care, they're getting directly referred now to us within our own system here. So those opportunities didn't exist on either end previously.
我是Marc。在我們整合Talkspace的過程中,我的意思是,當我們談到連續照護(continuum)時,其中一個重點是Talkspace以一種不同的方式獲取病人,主要與來自其他行為健康照護場域的病人來源無關。現在我們有機會把已在我們生態系中的病人導流過去、轉介到Talkspace,不論是在我們的門診服務或住院場域。反過來,我們現在也有機會——而且我們才剛開始看到——Talkspace生態系中的一些病人若需要進一步照護、需要更高層級的照護,現在會直接被轉介到我們這邊、進入我們自己的體系。所以這些機會在過去兩端都不存在。
They exist now, and we're just starting to see some of that come to fruition. I can't give you exact numbers yet, but we feel like we're off to a good start. The Talkspace folks have been very encouraged by the way that this has been set up thus far. Again, we're only into this for a few months. But the teams are working very well together. So we're very optimistic going forward. that this is going to make a real difference for us and for their business.
現在已經存在,而且我們才剛開始看到其中一些開始落地。我目前還無法提供確切數字,但我們覺得開局不錯。Talkspace團隊對目前為止的架構設計方式感到非常受鼓舞。再次強調,我們才進行了幾個月。但兩邊團隊合作得非常順暢。因此我們對未來非常樂觀,相信這將為我們以及他們的業務帶來實質差異。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Helpful. Thank you. And then just maybe just following on to that, as you think about what you have today, how do you think about just organic in terms of the outpatient push and then maybe even other tuck-ins around kind of virtual more broadly.
很有幫助。謝謝。另外也許再延伸一下,當你們看待目前已有的布局時,你們如何看待有機成長(organic),例如門診推進(outpatient push),以及更廣義的虛擬(virtual)領域可能還會有其他小型併購(tuck-ins)?
Marc Miller - President and Chief Executive Officer
Marc Miller - President and Chief Executive Officer
You're talking about non-Talkspace?
你指的是非Talkspace的部分?
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Yeah.
對。
Marc Miller - President and Chief Executive Officer
Marc Miller - President and Chief Executive Officer
I mean, we continue -- look, we've always had robust outpatient business, especially with our intensive outpatients, some of our partial hospitalization programs. But we're trying to expand even those in some of our locations where we didn't have it at all or we didn't have it as much. So we're certainly focused on that. We also have what we've talked about in previous quarters, 1,000 branches, which has been a newer effort in the last couple of years to expand into different areas in outpatient that's been going well, and we see further opportunities on the horizon to continue that expansion.
我的意思是,我們持續——你看,我們一直都有很強的門診業務,特別是我們的密集門診(intensive outpatient),以及部分住院計畫(partial hospitalization programs)的一些項目。但我們正嘗試在某些據點擴張這些服務——有些地方我們原本完全沒有,或是規模沒那麼大。所以我們當然聚焦在這一塊。此外,我們也有在前幾季談過的「1,000個據點(branches)」計畫,這是過去幾年較新的努力,目標是在門診的不同領域擴張;目前進展良好,我們也看到未來仍有進一步擴張的機會。
As far as other tuck-ins, other acquisitions, we're constantly looking. We're contacted often about that. And if something makes sense, price-wise, we'll certainly pursue it. But right now, I think that we're moving in the right direction in the areas that I just mentioned.
至於其他tuck-ins、其他併購,我們一直都在看。也經常有人就此與我們接洽。如果在價格等方面合理,我們當然會推進。但就目前而言,我認為我們在我剛提到的那些領域正朝正確方向前進。
Craig Hettenbach - Analyst
Craig Hettenbach - Analyst
Helpful. Thank you.
很有幫助。謝謝。
Operator
Operator
Jason Cassorla, Guggenheim Securities.
Jason Cassorla,Guggenheim Securities。
Jason Cassorla - Equity Analyst
Jason Cassorla - Equity Analyst
Great. Thanks. Good morning. Wanted to ask about behavioral. Obviously, strong volume up 2.1%, same facility up 4% or revenue up 4%, excluding out-of-period, supplemental same-facility EBITDA was only effectively flat. I guess, can you help in terms of the disconnect on the EBITDA growth side? Is that almost entirely explained by Laurel Ridge and same facility EBITDA growth for behavior what otherwise been in line with revenue growth? Or are there puts and takes there? Thanks.
好的。謝謝。早安。我想問一下行為健康(behavioral)。很明顯量能很強,總量成長2.1%,同院(same facility)成長4%或營收成長4%,排除跨期(out-of-period)與補充項目後,同院EBITDA實際上幾乎持平。我想,你能否協助解釋一下EBITDA成長端的落差?這幾乎完全可以用Laurel Ridge來解釋嗎?如果沒有Laurel Ridge,行為健康的同院EBITDA成長本來會與營收成長一致?還是其中還有其他拉抬與拖累因素(puts and takes)?謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
No. I think, Jason, in some -- to a large degree, you've answered your own question. Yeah, so I think that Laurel Ridge is probably the single biggest drag on the behavioral earnings improvement. Beyond that, as I said earlier, as we think about revenue growth from a pricing perspective, I think we're running towards the high end of our range for volumes, expected volumes towards the lower end of our range in pricing. I think some of that is a reflection of the fact that over the last several years, pricing has been very robust.
不。我想,Jason,在某種——很大程度上,你其實已經回答了你自己的問題。是的,所以我認為Laurel Ridge大概是行為健康獲利改善中最大的單一拖累因素。除此之外,如我先前提到的,從定價角度來看,我認為我們的量能表現接近我們區間的高端,而定價則預期接近我們區間的低端。我想其中一部分反映了過去幾年定價一直非常強勁。
Some of that has been the benefit of DPP. But even when you exclude that, our pricing and our contractual pricing has been very robust as we've been getting contractual price increases from payers, particularly Managed Medicaid payers who have not given us increases for several years. Unfortunately, obviously, after several years of that, we've started to anniversary some of that benefit and the pricing, I think, it has moved into that 2% to 3% range. But I think we're fairly confident that we'll be able to sustain that. And as we go into next year, et cetera, those comparisons will become easier.
其中一部分受惠於DPP。但即使排除該因素,我們的定價以及合約定價(contractual pricing)仍然非常強勁,因為我們一直從付款方取得合約價格調升,特別是多年未給我們調升的管理式Medicaid(Managed Medicaid)付款方。不幸的是,顯然在經過幾年之後,我們開始進入部分效益的週年比較(anniversary),因此我認為定價已經回到2%到3%的區間。但我認為我們相當有信心能夠維持這個水準。而且隨著我們進入明年等等,這些比較基期會變得更容易。
Jason Cassorla - Equity Analyst
Jason Cassorla - Equity Analyst
Got it. Thanks. Very helpful. And maybe just as a follow-up. I wanted to ask about the $10 million Medicaid supplemental headwind that you flagged for the fourth quarter of '27. Maybe could you just expand on how you're thinking about that estimate or which state programs are impacted in that quarter I know that the rules out there are still proposed, but just any other color related to that fourth quarter '27 headwind. And then any updates you may have around the potential DPP and provider tax headwinds from '28 and beyond would be helpful.
了解。謝謝。非常有幫助。另外也許再追問一下。我想問你們提到的、在2027年第四季會有1,000萬美元的Medicaid補充款(supplemental)逆風。能否再多談談你們如何看待這個估計,或是該季哪些州的計畫會受到影響?我知道相關規則目前仍是提案階段,但任何與2027年第四季逆風相關的補充說明都很有幫助。另外,若你們對2028年及之後可能出現的DPP與provider tax逆風有任何更新,也請分享。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So I mean as far as the headwinds in '28 and beyond, we've been disclosing those estimates in our SEC filings since the passage of OB3. We'll update those with our current filing. But they shouldn't be terribly different from what we've been disclosing to date. As far as the $10 million specific headwind in the fourth quarter of '27, Jason, I don't have that detail in front of me, but happy to discuss that off-line at some point.
好的。至於2028年及之後的逆風,我們自OB3通過以來,就一直在我們的SEC申報文件中揭露那些估計值。我們會在本次申報中更新。但它們應該不會與我們迄今揭露的內容有太大差異。至於2027年第四季那筆特定的1,000萬美元逆風,Jason,我手邊沒有更細的資料,但之後很樂意找時間私下再跟你討論。
Operator
Operator
Andrew Mok, Barclays.
Andrew Mok,巴克萊。
Andrew Mok - Analyst
Andrew Mok - Analyst
Hi, good morning. Just wanted to follow up on the acute dynamics in the quarter. Acute volumes were very strong, but Med-Surg mix was negative and weighed on acute pricing, how does the management team internalize this? Are you comfortable trading mix and price for stronger volumes? Or does this lead you to reconsider elements of your strategy. Thanks.
嗨,早安。我想追問一下本季急性照護的動態。急性量能非常強勁,但醫療外科(Med-Surg)組合為負,並對急性定價造成壓力,管理團隊如何內部看待這件事?你們是否願意以更強的量能來交換較差的組合與價格?或者這會讓你們重新思考策略中的某些要素?謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
So I mean, the answer, Andrew, is that's not a sort of conscious swap on our part. We didn't make a conscious decision to increase volumes, but decrease procedural volumes. Most of our medical volumes honestly come thorough to the emergency room. So those are patients who come to us. Procedural volumes tend to be more elective. We have done a lot of things to continue to build the procedural volumes, including investments in technology and things like robotics and things like OR capacity et cetera.
Andrew,我的意思是,答案是這並不是我們刻意做的交換。我們並沒有刻意決定要提高量能、但降低手術/處置量。我們的大部分醫療量其實是透過急診室進來的。所以那些是主動來到我們這裡的病人。手術/處置量則往往更偏選擇性(elective)。我們做了很多事情來持續建立手術/處置量,包括在技術上的投資,以及像是機器人、手術室(OR)容量等。
And it's paid off in the service lines that we mentioned earlier. The other issue, I think, is -- and we talked about -- and I think Marc talked about in his prepared remarks, we continue to try and increase our outpatient access points that includes things like FEDs, freestanding emergency department, it includes physician offices, all those things are designed to create more referrals into our procedural volumes. So attempting to do that as well. So again, I would just sort of emphasize the fact that we're looking to do both, to grow volumes overall, but also absolutely to grow surgical and procedural volumes to the extent that we can. We're not making a choice of medical admissions over surgical admissions.
而且這在我們先前提到的服務線上已經看到成效。我認為另一個議題是——我們也談到過——而且我想 Marc 在事先準備的發言中也提到,我們持續嘗試增加門診端的可近性據點,包括像 FED(獨立式急診部門,freestanding emergency department)、醫師診所等;這些都是為了帶來更多轉介,導入我們的手術/處置量。所以我們也在努力推動這件事。因此,我會再次強調,我們希望兩者都做:整體量能成長,同時也絕對希望在可行範圍內提升外科與手術/處置量。我們並沒有在醫療住院與外科住院之間做取捨。
Andrew Mok - Analyst
Andrew Mok - Analyst
Thank you.
謝謝你。
Operator
Operator
Ben Hendrix, RBC Capital Markets.
Ben Hendrix,RBC 資本市場。
Ben Hendrix - Assistant Vice President
Ben Hendrix - Assistant Vice President
Great. Thank you very much. As we get past the de novo ramp and the tax base integration, I think you noted that CapEx would normalize down to an $800 million range. It seems like that's getting closer to maintenance levels, but just are there any kind of development priorities you would rank order going forward following the integrations and de novo ramps? I mean, would you be focusing on further build-out of behavioral capabilities versus acute service lines versus tech and AI development? Kind of what -- how would you think about your priorities there? Thanks.
很好。非常感謝。隨著新設(de novo)項目爬坡期與稅基整合告一段落,我想你提到資本支出(CapEx)會回到約 8 億美元的常態水準。看起來這更接近維護性資本的水準,但想請教在完成整合與新設爬坡後,未來是否有任何開發優先順序會做排序?我的意思是,你們會更聚焦於擴建行為健康能力、急性服務線,還是科技與 AI 的開發?你們會如何思考這些優先事項?謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So I would just clarify a little bit, Ben, your comments. So as we go from $1 billion a year roughly that we've been spending on CapEx to $800 million going forward, that's largely because these large de novo projects that we've had over the last several years, the Palm Beach Gardens Hospital, the Riverside County, California replacement facility, West Henderson, we don't really have any full-scale de novo projects, and that's largely contributing to the decline. Use sort of characterize $800 million as maintenance capital, I think that's a bit of an exaggeration, but we sort of, I think, consider maybe 2% of our revenues to be devoted to maintenance capital. So something in that $250 million $300 million range.
好的。我先稍微澄清一下你的說法,Ben。當我們從過去每年大約 10 億美元的資本支出,走向未來的 8 億美元,主要原因是過去幾年我們有一些大型的新設(de novo)專案,例如 Palm Beach Gardens Hospital、加州 Riverside County 的替換設施、West Henderson;接下來幾年我們並沒有任何全規模的新設專案,而這是下降的主要原因。你把 8 億美元形容為維護性資本,我覺得有點誇大;我們大致認為維護性資本約占營收的 2%。所以大概是在 2.5 億到 3 億美元的區間。
So there's another $400 million -- $500 million, $550 million of expansionary capital in the $800 million, and that's new capacity, new beds, new ORs, new ERs, robotics in the acute care segment. And I think an emphasis on -- and we've touched on this in other ways in our comments here, an emphasis on outpatient growth and outpatient access points in both of the segments. So yes, I mean, I think the primary driver of the decline is just not having any of these big de novo projects in the pipeline over the next several years, but it certainly doesn't indicate and unwillingness on our part to continue to reinvest in the business and strategically in the areas that we think will drive growth in the future.
因此,在 8 億美元中,還有另外約 4 億到 5 億、5.5 億美元屬於擴張性資本,用於新增產能:新床位、新手術室(OR)、新急診室(ER),以及急性照護部門的機器人等。我認為還有一個重點——我們在這裡的其他評論也以不同方式提到過——就是強調門診成長與門診可近性據點,在兩個事業部門都是如此。所以是的,我認為下降的主要驅動因素就是未來幾年管線中沒有這些大型新設專案;但這絕不代表我們不願意持續再投資於業務,並在我們認為能驅動未來成長的領域進行策略性投資。
Ben Hendrix - Assistant Vice President
Ben Hendrix - Assistant Vice President
Thank you.
謝謝你。
Operator
Operator
Scott Fidel, Goldman Sachs.
Scott Fidel,高盛。
Scott Fidel - Analyst
Scott Fidel - Analyst
Hi. Thanks. Good morning. First question, just I appreciate the details that you gave us on the anticipated same directive payments headwind, would you be able to break that out between the mix of that between acute care and behavioral?
嗨,謝謝。早安。第一個問題,我很感謝你們提供關於預期「同指令支付」(same directive payments)逆風的細節;你們能否把其中急性照護與行為健康兩個部門的占比拆分說明?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
So Scott, I think what we've said historically is that the SDP payments are split pretty evenly between the two segments. And I think the reductions are similarly split.
Scott,我想我們過去一向的說法是,SDP 支付在兩個部門之間大致各占一半。而且我認為減少的部分也同樣是類似的分配。
Scott Fidel - Analyst
Scott Fidel - Analyst
Okay. And then -- just would be interested in an update on the health plan, the Medicare Advantage plan, which is getting quite -- you guys have been growing it pretty impressively the last couple of years, and it's getting quite sizable. But could you sort of talk about how the MLR trends in the business have been going this year? And then in terms of your bids for 2027, how you position those relative to growth versus margins? Thanks.
了解。接著——我也想請你們更新一下健康保險計畫,也就是 Medicare Advantage 計畫;你們過去幾年成長相當亮眼,規模也變得很可觀。但你們能否談談今年該業務的醫療損失率(MLR)趨勢如何?以及在 2027 年的投標(bids)方面,你們如何在成長與利潤率之間做定位?謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So you described the health plan as an MA plan. It is largely an MA plan. About 90% of its revenue comes from MA, but it does have about a 10% commercial mix as well. We talked about in 2026, a $25 million roughly tailwind from improvements at the health plan.
好的。你把健康計畫描述為 MA 計畫。它確實主要是 MA 計畫。大約 90% 的營收來自 MA,但也有約 10% 的商業保險組合。我們談到 2026 年,健康計畫改善將帶來約 2,500 萬美元的順風。
And I think we are largely tracking to that I think next year, there'll be sort of a normal amount of growth as the revenue has grown, but not expecting a material impact up or down in terms of our earnings in 2027 as a result of the health plan. Obviously, the health plan from our perspective continues to provide a significant benefit to our acute care hospitals. We operate the plan only in those markets in which we have acute care hospitals.
我認為我們大致正朝這個方向推進;我想明年隨著營收成長,會有一個正常幅度的成長,但我們不預期健康計畫在 2027 年會對我們的獲利造成顯著的正面或負面影響。當然,從我們的角度來看,健康計畫持續為我們的急性照護醫院帶來顯著效益。我們只在我們設有急性照護醫院的市場中經營該計畫。
Scott Fidel - Analyst
Scott Fidel - Analyst
Steve, could you just on the margins, just sort of where you view the MA pretax margin now after getting that $25 million sort of improvement in the underlying earnings. And that's it for me. Thanks.
Steve,關於利潤率,你能否談一下在那約 2,500 萬美元的改善、也就是基礎獲利提升之後,你們目前如何看待 MA 的稅前利潤率?我這邊就這樣。謝謝。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. We think that historically, the plan has operated with sort of either low negative single-digit margins or low positive single-digit margins. I think the improvement last year is because the plan is operating in low positive single-digit margins. And I think that's our expectation that it will continue to do so over the next couple of years.
好的。我們認為歷史上,該計畫的利潤率大致是在低個位數的負值,或低個位數的正值。我認為去年的改善,是因為該計畫目前運作在低個位數的正利潤率。而且我們預期未來幾年也會持續如此。
Scott Fidel - Analyst
Scott Fidel - Analyst
Thank you.
謝謝你。
Operator
Operator
Benjamin Rossi, JPMorgan.
Benjamin Rossi,摩根大通。
Benjamin Rossi - Analyst
Benjamin Rossi - Analyst
Hey, good morning. Thanks for taking my question. I've heard you describe a few offset opportunities in recent quarters related to your payer mix initiatives, your outpatient network development across segments, some of your technology investments and then some of your expense initiatives or things like supplies I know you aren't providing formal 2027 commentary, but could you walk us through how those initiatives are coming together and where you expect to see contribution to margins in the coming quarters.
嗨,早安。謝謝讓我提問。我聽到你們在最近幾季提到一些可用來抵銷的機會,包括與付款方組合(payer mix)相關的倡議、跨部門的門診網絡開發、一些技術投資,以及一些費用端的倡議或像是耗材等。我知道你們不提供正式的 2027 年展望,但你們能否帶我們梳理一下這些倡議如何整合推進,以及你們預期在接下來幾季哪些方面會對利潤率帶來貢獻。
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah, Ben, I think you've done a decent job of framing your question around the things that we have already discussed. As we think about the challenges that will come, especially from OB3 in the next few years, whether that's Medicaid work requirements in '27 and '28 or the Medicaid supplemental reductions mostly in '28 and beyond. A number of things that we are trying to address. Technology developments, we've talked in previous quarterly calls about the things that we're doing in revenue cycle to improve revenue cycle performance. We had a very large third-party consulting exercise in our acute care revenue cycle in the last several -- 18 months or so.
是的,Ben,我認為你已經相當不錯地把你的問題框定在我們先前已討論過的事項上。當我們思考未來將到來的挑戰時,特別是未來幾年來自 OB3 的挑戰,不論是 '27 與 '28 的 Medicaid 工作要求,或是主要在 '28 及之後的 Medicaid 補充款削減。我們正嘗試處理多項事情。技術發展方面,我們在先前的季度電話會議中談過我們在收入循環(revenue cycle)所做的工作,以改善收入循環績效。在過去約 18 個月左右,我們在急性照護收入循環方面進行了一項非常大型的第三方顧問專案。
We're undergoing a similar exercise in behavioral developing technology, AI and otherwise to help us do that, developing technology, AI and otherwise to help us control length of stay, better control length of stay in acute care. I think you alluded to this in your question, a lot of the outpatient emphasis in behavioral, whether that's Talkspace or Thousand Branches or just the efforts within our existing facilities, really have the double benefit of meeting demand where patients are looking for it in the outpatient setting, but also as we build outpatient we're really shifting our payer mix away from Medicaid and more to commercial and Medicare because that's where that's where we think the growth is, and that helps us avoid some of these Medicaid cuts. So doing all those things, again, in terms of their specific impact and their specific impact in 2027. I think we'll provide more color on that in February.
我們也正在行為健康領域進行類似的專案,發展技術、AI 等等來協助我們做到這點,發展技術、AI 等等來幫助我們控制住院天數,在急性照護中更好地控制住院天數。我想你在問題中也提到這點:行為健康領域對門診的重點投入,不論是 Talkspace 或 Thousand Branches,或只是我們在既有設施內的努力,確實具有雙重效益:一方面在門診場景滿足病患正在尋求的需求;另一方面,隨著我們擴建門診,我們也正把付款方組合(payer mix)從 Medicaid 轉移,更多轉向商業保險與 Medicare,因為我們認為成長就在那裡,而這也有助於我們避開部分 Medicaid 的削減。因此做所有這些事情,再次回到它們的具體影響,以及它們在 2027 年的具體影響。我想我們會在二月提供更多細節。
Darren Lehrich - Vice President of Investor Relations
Darren Lehrich - Vice President of Investor Relations
Stephen, I think we have time for one more question.
Stephen,我想我們還有時間再問一個問題。
Operator
Operator
Sarah James, Cantor Fitzgerald.
Sarah James,Cantor Fitzgerald。
Sarah James - Analyst
Sarah James - Analyst
Thank you. Just a quick clarification on exchanges? And then I have a question on talk. So on the exchanges, when you talked about at least a $15 million headwind year-over-year, that's just annualized in the second half. So I wanted to clarify, does that mean that assumes flat exchange market size from '26 to '27. Is that what that $15 million is based on?
謝謝。先就交易所(exchanges)做個快速釐清?然後我有一個關於 Talk 的問題。關於交易所,你提到年對年(year-over-year)至少有 1,500 萬美元的不利因素(headwind),那只是下半年年化後的數字。所以我想確認一下,這是否表示你假設從 '26 到 '27 交易所市場規模持平。那 1,500 萬美元是基於這個假設嗎?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So Sarah, what we've said this year is we expected an $85 million negative impact from the reduction in exchange coverage. $35 million of that was in the first half of the year, $50 million was in the second half of the year. We're assuming that at a minimum, the $50 million is the run rate into next year. So that's a $15 million -- that's where the $15 million headwind comes from.
是的。Sarah,我們今年所說的是,我們預期因交易所保險覆蓋縮減而帶來 8,500 萬美元的負面影響。其中 3,500 萬美元發生在上半年,5,000 萬美元發生在下半年。我們假設至少這 5,000 萬美元會作為進入明年的運行水準(run rate)。所以這就是 1,500 萬美元——也就是 1,500 萬美元不利因素的來源。
And then what we further said is that to the degree that there are further reductions in exchange volumes next year, that could create an incremental headwind, but we really won't know that until some of that enrollment data becomes more widely available.
另外我們也說過,若明年交易所投保量(exchange volumes)進一步下降,可能會造成額外的不利因素,但在部分投保數據更廣泛可得之前,我們其實不會知道。
Sarah James - Analyst
Sarah James - Analyst
Got it. And then on Talk, what do you need to see in the first 12 months, this proof of concept wise to show that step-down capture is working. In the past, you've referred to currently capturing low to mid-single digits and step down possibly reaching double digit over time. So what is that timeline? Is that like a five-year goal or 10-year goal? How do we think about that growth?
了解。那關於 Talk,在最初 12 個月內,就概念驗證(proof of concept)而言,你們需要看到什麼,才能證明分級轉介(step-down)承接(capture)正在奏效?過去你們提到目前承接率在低到中個位數,而 step-down 隨時間可能達到雙位數。那時間表是什麼?這是五年目標還是十年目標?我們該如何看待這個成長?
Steve Filton - Chief Financial Officer
Steve Filton - Chief Financial Officer
Yeah. So Sarah, I think the way it will be reflected will be an increase in outpatient activity at both UHS and a Talkspace. So today, our outpatient visits, I think, in the third quarter grew by about 3%. I think Talkspace just on an organic basis on their own, their visits or procedures or units increased by more than UHS standalone and combined would have been more like 5% on a pro forma basis. I think our expectation is that both of those numbers will accelerate as a result of the merger and the continued integration of the two platforms.
是的。Sarah,我認為它呈現出來的方式會是 UHS 與 Talkspace 兩邊的門診活動增加。以今天來看,我們的門診就診次數在第三季大約成長了 3%。我想 Talkspace 單就其自身的自然成長(organic basis)而言,他們的就診、處置或單位數的增幅高於 UHS 單獨的增幅;若合併後以備考(pro forma)基礎來看,會更接近 5%。我們的預期是,隨著合併以及兩個平台持續整合,這兩個數字都會加速。
And so yes, that's, I think, what will provide the proof of concept. And I think as we said earlier, we're not going to see a ton of that in the first 12 months. But beginning, I think, in the next 12 months after that, we'll start to see that benefit. And I think it will continue to be sustainable for many years beyond that.
所以是的,我想這就是能提供概念驗證的部分。而且如同我們先前所說,我們在前 12 個月不會看到太多這方面的成果。但我認為從接下來再往後的 12 個月開始,我們會開始看到這個效益。而且我認為在那之後的許多年,這都會是可持續的。
Sarah James - Analyst
Sarah James - Analyst
Thank you.
謝謝。
Operator
Operator
Thank you. This concludes the question-and-answer session. I would now like to turn it back to Darren for closing remarks.
謝謝。問答環節到此結束。我現在想把時間交回給 Darren 作結語。
Darren Lehrich - Vice President of Investor Relations
Darren Lehrich - Vice President of Investor Relations
Thanks, Stephen, and thank you, everyone, for participating in today's call and for your interest in UHS. Have a great rest of your day.
謝謝你,Stephen,也謝謝各位參與今天的電話會議並關注 UHS。祝各位今天剩下的時間愉快。
Operator
Operator
Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.
感謝各位參與今天的會議。本節目到此結束。您現在可以掛線。